WASHINGTON — Novo Nordisk’s newly received permission to market the center advantages of its weight problems drug Wegovy might present a backdoor solution to increase entry to the drug for folks on Medicare, consultants informed STAT.
At present, Medicare is prohibited by legislation from overlaying medicines for weight problems remedy alone. Whereas firms that manufacture wildly fashionable anti-obesity medicines and their allies haven’t been profitable in lobbying Congress to vary the legislation, the Meals and Drug Administration’s transfer might give medical doctors an avenue to prescribe the medicines to some Medicare sufferers.
Wegovy’s new label signifies that the drug can be utilized to scale back the chance of main coronary heart issues for people who find themselves obese or overweight and have present coronary heart illness, Novo mentioned in a press release Friday.
Get limitless entry to award-winning journalism and unique occasions.
Subscribe